MANE

SCHEDULE 13D/A - Veradermics, Inc (0001827635) (Subject)

4 - Veradermics, Inc (0001827635) (Issuer)

3 - Veradermics, Inc (0001827635) (Issuer)

4 - Veradermics, Inc (0001827635) (Issuer)

4 - Veradermics, Inc (0001827635) (Issuer)

EFFECT - Veradermics, Inc (0001827635) (Filer)

144/A - Veradermics, Inc (0001827635) (Subject)

4 - Veradermics, Inc (0001827635) (Issuer)

424B3 - Veradermics, Inc (0001827635) (Filer)

10-Q - Veradermics, Inc (0001827635) (Filer)

8-K - Veradermics, Inc (0001827635) (Filer)

Positive topline results from open-label Phase 2 Study ‘207’ evaluating VDPHL01 in female pattern hair loss demonstrated rapid onset and consistent hair growth Completion of patient enrollment for Phase 2/3 Study ‘306’, a 556 participant, registration-directed trial evaluating VDPHL01 in female pattern hair loss, marking a milestone in the development of the potential first oral prescription treatment for women; topline readout anticipated in 1H27 VDPHL01 has the potential to be the first extended-release oral minoxidil therapy for women and men with pattern hair loss, a condition affecting an estimated 30 million women and 50 million men in the United States Company remains on track

S-1 - Veradermics, Inc (0001827635) (Filer)

SCHEDULE 13G - Veradermics, Inc (0001827635) (Subject)

Veradermics, Incorporated (NYSE:MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced the presentation of data from the Phase 2/3 Study ‘302’ of VDPHL01 in male patients with mild-to-moderate pattern hair loss. The subgroup analysis data were shared in a poster presentation on July 16, 2026, and will be shared in an oral presentation on July 17, 2026, during the 2026 American Academy of Dermatology (AAD) Innovation Academy in New York City. Study ‘302’ is a randomized, double-blind, placebo-controlled Phase 2/3 trial evaluating treatment with VDPHL01, a proprietary extended-release oral min

8-K - Veradermics, Inc (0001827635) (Filer)

B. Riley Securities initiated coverage of Veradermics with a rating of Buy and set a new price target of $170.00

VDPHL01, a novel orally-administered extended-release minoxidil formulation, achieved fast onset of hair growth with the majority of study participants reporting improvement in hair coverage as early as Month 2 and consistent treatment effect with approximately 88.9% (once daily) and 90.0% (twice-daily dosing) of patients reporting ‘improved’ or ‘much improved’ outcomes at Month 6 Robust hair growth was observed with a mean increase in non-vellus target area hair count (TAHC) of 22.7 hairs/cm² and 23.3 hairs/cm² at Month 6, in once and twice daily dosing regimens, respectively VDPHL01 demonstrated a favorable safety and tolerability profile in females that was generally consistent with

Conference call will take place on Wednesday, July 15, 2026 at 8:00 am ET Veradermics, Incorporated (NYSE:MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced it will host an investor call and live webcast on Wednesday, July 15, 2026 at 8:00 am ET to review results from female treatment arms of the Phase 2 open-label Study ‘207’ evaluating VDPHL01, a proprietary extended-release oral minoxidil tablet, in males and females with mild-to-moderate pattern hair loss. Webcast Details: Time: Wednesday, July 15, 2026 at 8:00 a.m. ET. Joining: The event and the accompanying slides will be availab

Needham initiated coverage of Veradermics with a rating of Buy and set a new price target of $136.00

SEATTLE and VANCOUVER, British Columbia, June 02, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. ("Achieve" or the "Company") (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced that Jeffrey Farrow and Reid Waldman, MD have been appointed to its Board of Directors. "Jeffrey and Reid are exactly the kinds of operators you want around a board table when a company is preparing for its first launch," said Lucian Iancovici, MD, incoming Chairman of the Board of Directors of Achieve. "Jeffrey has lived the playbook of taking specialty companies from lat

Veradermics, Incorporated (NYSE:MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced that company management will participate in the following upcoming investor conferences in June: Jefferies Global Healthcare Conference on Wednesday, June 3 in New York, NY Reid Waldman, M.D., Chief Executive Officer of Veradermics, and Mark Neumann, Chief Commercial and Strategy Officer of Veradermics, will host a corporate presentation at 3:10 p.m. ET Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8 in Miami, FL Reid Waldman, M.D., Chief Executive Officer of Veradermi

Veradermics, Incorporated (NYSE:MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced that topline results from Phase 2/3 ‘302' Study of VDPHL01 will be presented at the 2026 World Congress for Hair Research on May 30, 2026. The data to be presented includes positive topline results, shared by the company in April 2026, from Part A of its randomized, double-blind, placebo-controlled Phase 2/3 clinical trial (Study ‘302') evaluating VDPHL01, a proprietary extended-release oral minoxidil formulation, in over 500 males with mild-to-moderate pattern hair loss. Veradermics believes th

SCHEDULE 13G/A - Veradermics, Inc (0001827635) (Subject)

D - Veradermics, Inc (0001827635) (Filer)